Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional) | PA 19 112

Opportunity Information: Apply for PA 19 112

The National Institutes of Health (NIH) funding opportunity titled Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional), Funding Opportunity Number PA 19 112, supports research projects aimed at reducing heart and blood vessel damage linked to cancer therapies while still preserving or improving cancer outcomes. The core idea is that more patients are living longer with and after cancer, but many experience cardiovascular complications from treatment, so this FOA is looking for strong, team-based studies that can identify who is at greatest risk and test practical ways to prevent, detect earlier, or better manage these complications across the cancer care timeline.

A central focus is improving how clinicians evaluate cardiovascular risk before cancer treatment starts and how they integrate that risk information into real-world cancer treatment planning. Applications are expected to bring together cancer and cardiovascular expertise to develop or validate approaches that combine evidence-based oncology regimens with cardiovascular screening, diagnostic tools, and clinical management strategies. In other words, the FOA is not just interested in describing cardiotoxicity after it happens; it prioritizes work that can shift care toward prevention and early intervention, with methods that fit into routine treatment decisions.

The FOA explicitly targets adverse effects associated with a broad range of anti-cancer treatments. This includes traditional cytotoxic chemotherapies, newer targeted agents, immunomodulatory therapies (including immunotherapies), and radiation therapy. It also covers problems that arise during active treatment as well as those that develop later in survivorship, recognizing that cardiovascular harm may emerge months or years after therapy. Importantly, the cardiotoxic outcomes of interest are framed using cardiac- and vascular-specific Common Terminology Criteria for Adverse Events (CTCAE), which signals an emphasis on standardized, clinically meaningful definitions of toxicity that can be compared across studies and applied in clinical settings.

The mechanism is an R01 research project grant, and clinical trials are optional, meaning applicants can propose either clinical trial or non-trial research designs as long as the study addresses the program goals. The opportunity is categorized as discretionary funding and falls under education and health-related activity areas, with CFDA numbers 93.393 and 93.837. While the listing includes an original closing date of 2022-01-07 and does not provide an award ceiling or expected number of awards in the provided summary, the scientific scope is clear: collaborative, translationally relevant research that improves cardiovascular safety without compromising effective cancer treatment.

Eligibility is broad and includes many types of domestic organizations and governments, such as state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations (other than small businesses); small businesses; and Native American tribal governments and organizations, including federally recognized tribal governments and other tribal organizations. The FOA also highlights additional eligible applicant categories intended to encourage participation from diverse and underserved communities and institutional types, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. (foreign) organizations.

Overall, this grant opportunity is aimed at strengthening the evidence base for cardio-oncology by supporting projects that can (1) identify and characterize patient subgroups most vulnerable to treatment-related cardiotoxicity, (2) improve pre-treatment cardiovascular risk assessment, and (3) integrate cancer therapy choices with cardiovascular monitoring and management strategies that reduce harm. The intended end result is more personalized cancer care that protects cardiovascular health, improves quality of life, and supports long-term survivorship without sacrificing the effectiveness of cancer treatment.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.837.
• This funding opportunity was created on 2018-12-17.
• Applicants must submit their applications by 2022-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 19 112

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: